182 related articles for article (PubMed ID: 35155195)
1. Targeting Thyrointegrin αvβ3 Using Fluorobenzyl Polyethylene Glycol Conjugated Tetraiodothyroacetic Acid (NP751) in Acute Myeloid Leukemia.
Darwish NHE; Glinsky GV; Sudha T; Mousa SA
Front Oncol; 2021; 11():793810. PubMed ID: 35155195
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of fluorobenzyl polyethylene glycol conjugated tetraiodothyroacetic acid (NP751), a novel anticancer thyrointegrin α
Fujioka K; Hay BA; Godugu K; Mousa SA
Front Pharmacol; 2022; 13():902141. PubMed ID: 36518666
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel thyrointegrin αvβ3 antagonist fb-PMT (NP751) in the management of human glioblastoma multiforme.
Godugu K; Hay BA; Glinsky GV; Mousa SA
Neurooncol Adv; 2023; 5(1):vdac180. PubMed ID: 36879662
[TBL] [Abstract][Full Text] [Related]
4. Novel Polyethylene Glycol-Conjugated Triazole Derivative with High Thyrointegrin αvβ3 Affinity in Acute Myeloid Leukemia Management.
Sudha T; Godugu K; Darwish NHE; Nazeer T; Mousa SA
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439224
[TBL] [Abstract][Full Text] [Related]
5. New Thyrointegrin α
Hay BA; Godugu K; Darwish NHE; Fujioka K; Sudha T; Karakus OO; Mousa SA
J Med Chem; 2021 May; 64(9):6300-6309. PubMed ID: 33886292
[TBL] [Abstract][Full Text] [Related]
6. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin α
Rajabi M; Godugu K; Sudha T; Bharali DJ; Mousa SA
Bioconjug Chem; 2019 Dec; 30(12):3087-3097. PubMed ID: 31714064
[TBL] [Abstract][Full Text] [Related]
7. Anti-Cancer Activities of Thyrointegrin α
Godugu K; Rajabi M; Mousa SA
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204997
[TBL] [Abstract][Full Text] [Related]
8. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin α
Sudha T; Godugu K; Glinsky GV; Mousa SA
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453545
[TBL] [Abstract][Full Text] [Related]
9. Discovery of dual targeting PEGylated BG-P
Ozen Karakus O; Godugu K; Mousa SA
Bioorg Med Chem; 2021 Aug; 43():116278. PubMed ID: 34157571
[TBL] [Abstract][Full Text] [Related]
10. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
11. A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML).
Ando H; Murakami Y; Eshima K; Ishida T
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1485. PubMed ID: 34173723
[TBL] [Abstract][Full Text] [Related]
12. Correction to "Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin α
Rajabi M; Godugu K; Sudha T; Bharali DJ; Mousa SA
Bioconjug Chem; 2021 Apr; 32(4):859. PubMed ID: 33689298
[No Abstract] [Full Text] [Related]
13. Anticancer Efficacy and Mechanisms of a Dual Targeting of Norepinephrine Transporter and Thyrointegrin αvβ3 Antagonist in Neuroblastoma.
Godugu K; Karakus OO; Fujioka K; Glinsky GV; Mousa SA
J Cancer; 2022; 13(8):2594-2606. PubMed ID: 35711848
[No Abstract] [Full Text] [Related]
14. Correction to "Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin α
Rajabi M; Godugu K; Sudha T; Bharali DJ; Mousa SA
Bioconjug Chem; 2023 Feb; 34(2):453. PubMed ID: 36709499
[No Abstract] [Full Text] [Related]
15. Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice.
Gopalakrishnapillai A; Kolb EA; Dhanan P; Bojja AS; Mason RW; Corao D; Barwe SP
Front Oncol; 2016; 6():162. PubMed ID: 27446808
[TBL] [Abstract][Full Text] [Related]
16. RETRACTED: Godugu et al. Anti-Cancer Activities of Thyrointegrin α
Godugu K; Rajabi M; Mousa SA
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792024
[TBL] [Abstract][Full Text] [Related]
17. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia.
Her Z; Yong KSM; Paramasivam K; Tan WWS; Chan XY; Tan SY; Liu M; Fan Y; Linn YC; Hui KM; Surana U; Chen Q
J Hematol Oncol; 2017 Oct; 10(1):162. PubMed ID: 28985760
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.
Giri B; Gupta VK; Yaffe B; Modi S; Roy P; Sethi V; Lavania SP; Vickers SM; Dudeja V; Banerjee S; Watts J; Saluja A
J Transl Med; 2019 May; 17(1):163. PubMed ID: 31109340
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
[TBL] [Abstract][Full Text] [Related]
20. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
Sami SA; Darwish NHE; Barile ANM; Mousa SA
Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
